AlphaStocks
6.5
Consider Buy

Progyny, Inc. (PGNY)

As of Sep 19, 2026, Progyny, Inc. (PGNY) scores 6.5/10 on AlphaStocks' five-model composite, #26 of 168 Health Care stocks. At $27, PGNY trades 91% above its model fair value of $14.

Health Care / Health Care Services

S&P SmallCap 600

$27.15

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 19, 2026

#26out of 168 in Health Care

Is Progyny, Inc. a Good Investment in 2026?

Progyny, Inc. (PGNY) scores 6.5 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates Progyny, Inc. as Attractive (5/9). However, the Graham model rates it Caution — Significantly above fair value. Progyny, Inc. currently trades 91% above its estimated fair value of $14. Progyny, Inc. ranks #26 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E41.7ROE8.5Market Cap2B

Estimated Fair Value

$14.2491% above

Trading above estimated fair value. P/e of 42x implies high growth expectations.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 1.6 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Progyny, Inc. (PGNY) a good investment?
As of Sep 19, 2026, Progyny, Inc. (PGNY) scores 6.5/10 on AlphaStocks' five-model composite, #26 of 168 Health Care stocks. At $27, PGNY trades 91% above its model fair value of $14. That is a middle-of-the-pack score with no strong signal either way.
What is Progyny, Inc.'s Piotroski F-Score?
Progyny, Inc.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is PGNY overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $14, PGNY appears overvalued. The stock currently trades 91% above its estimated fair value. Trading above estimated fair value. P/e of 42x implies high growth expectations.
How does PGNY compare to other Health Care stocks?
Progyny, Inc. ranks #26 out of 168 stocks in the Health Care sector, placing it in the top 15% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about PGNY?
AlphaStocks evaluates PGNY using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Lynch: Neutral. These models are combined into a single composite score of 6.5/10.

Similar Stocks

DVAMDDGX

Compare PGNY with

DVA vs PGNYMD vs PGNYDGX vs PGNY

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer